# Pizarra — PT-pseudo_c9d31197c533 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c9d31197c533
Task: 1

Encounter: Urology - outpatient on 02 Feb 2025.
Referrer: Dr. R. Visser (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 61-year-old male
  - PSA: 10.92 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.26 ng/mL²
  - PSA velocity: 1.16 ng/mL/yr
  - Prior PSA: 10.0 ng/mL
  - Prostate volume: 42.0 mL
  - Months since last PSA: 1
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8727174 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Osteoarthritis
  - Problem list / PMHx: Hypertension, Osteoarthritis
  - Current medication: valsartan, lisinopril, paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 10.92 ng/mL. PI-RADS 5. PSAD 0.26. Prostate volume 42 mL. DRE nodus. csPCa 0.87.

Vitals: weight 73 kg, height 172 cm, BMI 24.7, BP 125/92 mmHg, HR 75 bpm. Smoking: Non-smoker.

Chief complaint: Persistent PSA elevation and confirmation of Gleason 4+3 carcinoma on prior biopsy bucket "Positive" warrant clinical reassessment.

History: A 61-year-old retired bank clerk entered the diagnostic pathway in late 2023 due to elevated PSA levels. He is a non-smoker with a background of hypertension treated by valsartan and lisinopril, plus osteoarthritis managed with paracetamol PRN. Divorced, he resides in an assisted-living facility and enjoys tennis twice weekly, averaging 22 units of alcohol each week. With his daughter handling correspondence under consent, he recently completed baseline memory screening and a sleep clinic assessment for suspected obstructive sleep apnoea. A prior 12-core biopsy confirmed Gleason 4+3 disease. He experiences chronic lower urinary tract symptoms yielding an IPSS of 20/35, yet denies urinary retention, haematuria, unexplained weight loss, or bone pain. His overall condition remains stable.

Physical examination: DRE — texture: moderately enlarged gland with a firm, discrete nodule palpable in the left peripheral zone; remainder symmetrically smooth without induration. General examination shows stable vital signs, unremarkable systemic findings, and no palpable lymphadenopathy or hepatosplenomegaly.

Patient info: retired bank clerk; Divorced; Lives in assisted-living facility.
Next of kin: Nephew.

Lifestyle: alcohol 22 units / week; exercise Tennis 2x/week; IPSS score: 20/35 (severe LUTS).

Recent other appointments: Memory clinic — baseline screening; Sleep clinic — suspected obstructive sleep apnoea.
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.40 +/- 0.17   (95% CI 0.08-0.73)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.17  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.97 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and management agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with current imaging and lab data, warrants a re-biopsy decision, as the protocol expert found the visible panel insufficient. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, which included the PI-RADS 5 score, PSA of 10.92 ng/mL, and prior positive biopsy status. It could not weigh the clinical context such as the specific PSA velocity (1.16 ng/mL/yr), the prostate volume (42.0 mL), the DRE finding of a nodule, or the patient's history of severe LUTS (IPSS 20/35).

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.40 +/- 0.17. The high aleatoric uncertainty (H=0.97) indicates the model cannot distinguish between the two outcomes based on the input. This is dangerous because the patient has a high PI-RADS 5 score and a rising PSA velocity, which are strong indicators that the model's suggestion is likely missing critical progression signals.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
1. radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
2. psa_trend - What is the serial PSA trend beyond the headline value?
3. previous_notes - What was the prior grade, surveillance pathway, and management agreement?
4. previous GP / urology consultation notes - What is the current management plan regarding the prior positive biopsy?

GUIDELINE ANCHOR
Guidelines suggest that the decision must depend on whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Amsterdam UMC (location AMC) | 15 January 2025 | Multiparametric MRI Prostate
The lesion is a PI-RADS 5 in the left peripheral zone, measuring approximately 18 x 14 x 12 mm. No extraprostatic extension or seminal vesicle invasion is identified.
get_psa_trend
[{"date": "Dec 2023", "val": 4.5}, {"date": "Mar 2024", "val": 5.6}, {"date": "Jul 2024", "val": 7.0}, {"date": "Oct 2024", "val": 8.7}, {"date": "Feb 2025", "val": 10.92}]
get_previous_notes
[{"date": "07 Jun 2024", "author": "Dr. R. Visser (GP)", "text": "Clinical review addressed a fluctuating PSA trajectory, recording 9.3 ng/mL in March followed by 8.6 ng/mL in July 2024. Earlier tissue sampling established Gleason 4+3 disease. Hypertension remains well-managed through valsartan and lisinopiln therapy."}]

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not require them, and the retrieved documents did not raise any specific questions requiring this panel.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion identified, which is a high-risk finding.
- PSA trend: Rising trajectory from 4.5 ng/mL (Dec 2023) to 10.92 ng/mL (Feb 2025), showing significant progression.
- Previous notes: Prior biopsy confirmed Gleason 4+3 disease, and the notes document a fluctuating PSA trajectory prior to the current visit.

AGAINST sampling this patient now:
- Previous notes: No explicit mention of an active surveillance protocol or a specific management agreement regarding the prior positive biopsy.

WHERE THIS LEANS
The evidence strongly supports re-biopsy due to the high-risk PI-RADS 5 finding and the clear, significant upward trajectory of the PSA over time, which aligns with the guideline criterion that requires re-evaluation when prior diagnosis exists.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

REOPENING THE BLACKBOARD (round 2 of 2).

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence (high PI-RADS 5 lesion and significant PSA progression) strongly supports the decision to re-biopsy, satisfying the protocol criterion that the panel must determine the next step.

WHY: the agenda WAS fulfilled and the participants still disagree, so this is a disagreement about INTERPRETATION, not about missing data. DO NOT OPEN ANY FURTHER DOCUMENT - there is nothing left that would settle it, and an extra reveal costs precision for nothing. Instead, go back to what is already on the board and answer one question: which of the two positions is supported by a retrieved finding, and which one is supported only by the visible panel that every participant could already see? Name that finding.

---

# Ronda 2

## [9] GAPS AND DOUBTS (round 2)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, which included the PI-RADS 5 score, PSA of 10.92 ng/mL, and prior positive biopsy status. It could not weigh the clinical context such as the specific PSA velocity (1.16 ng/mL/yr), the prostate volume (42.0 mL), the DRE finding of a nodule, or the patient's history of severe LUTS (IPSS 20/35).

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.40 +/- 0.17. The high aleatoric uncertainty (H=0.97) indicates the model cannot distinguish between the two outcomes based on the input. This is dangerous because the patient has a high PI-RADS 5 score and a rising PSA velocity, which are strong indicators that the model's suggestion is likely missing critical progression signals.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
1. radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
2. psa_trend - What is the serial PSA trend beyond the headline value?
3. previous_notes - What was the prior grade, surveillance pathway, and management agreement?
4. previous GP / urology consultation notes - What is the current management plan regarding the prior positive biopsy?

GUIDELINE ANCHOR
Guidelines suggest that the decision must depend on whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

## [10] EVIDENCE REPORT (round 2)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Amsterdam UMC (location AMC) | 15 January 2025 | Multiparametric MRI Prostate
The lesion is a PI-RADS 5 in the left peripheral zone, measuring approximately 18 x 14 x 12 mm. No extraprostatic extension or seminal vesicle invasion is identified.

get_psa_trend
[{"date": "Dec 2023", "val": 4.5}, {"date": "Mar 2024", "val": 5.6}, {"date": "Jul 2024", "val": 7.0}, {"date": "Oct 2024", "val": 8.7}, {"date": "Feb 2025", "val": 10.92}]

get_previous_notes
[{"date": "07 Jun 2024", "author": "Dr. R. Visser (GP)", "text": "Clinical review addressed a fluctuating PSA trajectory, recording 9.3 ng/mL in March followed by 8.6 ng/mL in July 2024. Earlier tissue sampling established Gleason 4+3 disease. Hypertension remains well-managed through valsartan and lisinopiln therapy."}]

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not require them, and the retrieved documents did not raise any specific questions requiring this panel.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion identified in the left peripheral zone.
- PSA trend: Significant progression from 4.5 ng/mL (Dec 2023) to 10.92 ng/mL (Feb 2025).
- Previous notes: Prior biopsy confirmed Gleason 4+3 disease, and notes document a fluctuating PSA trajectory prior to the current visit.

AGAINST sampling this patient now:
- Previous notes: No explicit mention of an active surveillance protocol or a specific management agreement regarding the prior positive biopsy.

WHERE THIS LEANS
The evidence strongly supports re-biopsy due to the high-risk PI-RADS 5 finding and the clear, significant upward trajectory of the PSA over time, which aligns with the guideline criterion that requires re-evaluation when prior diagnosis exists.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [11] CLOSING CHECK (round 2)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The evidence strongly supports re-biopsy based on the high-risk PI-RADS 5 finding and significant PSA progression, satisfying the protocol criterion. The disagreement remains an interpretation of the evidence, not a lack of data.

The chair decides on the record as it stands.

## [12] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

The conference reached a split between deferral and biopsy, with the evidence leaning towards biopsy due to the high-risk PI-RADS 5 finding and the significant PSA progression from 4.5 ng/mL to 10.92 ng/mL. The statistical prior suggested no biopsy, but the retrieved evidence, specifically the PI-RADS 5 lesion and the PSA trend, overturned this by providing strong progression signals. The guideline criterion abstained because the panel was insufficient, leaving the interpretation of the retrieved data as the deciding factor.

Variables that carried weight: bx=noted, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
